DTI for Injection

DTI for Injection



Korea United Pharm [KR]


Concise Prescribing Info
Metastatic malignant melanoma. 2nd-line therapy for Hodgkin's disease in combination w/ other effective agents.
Dosage/Direction for Use
Max: 200 mg/m2 as slow IV inj. Doses ranging from 200-850 mg/m2 should be administered as IV infusion over 15-30 min. Hodgkin's disease In combination w/ other effective drugs: 150 mg/m2/day for 5 days. May be repeated every 4 wk. Alternatively, 375 mg/m2 on Day 1 repeated every 15 days. Malignant melanoma Recommended dose: 2-4.5 mg/kg/day for 10 days. May be repeated at 4 wk intervals. Alternatively, 250 mg/m2/day IV for 5 days, repeated every 3 wk.
History of hypersensitivity. Patients w/ leucopenia &/or thrombocytopenia, severe liver or kidney diseases. Pregnancy & lactation.
Special Precautions
Bone marrow suppression, leukopenia, thrombocytopenia, anemia may occur; monitor CBC w/ differential. Hepatic necrosis; hepatotoxicity w/ hepatic vein thrombosis & hepatocellular necrosis. Antiemetics are recommended. Extravasation & hypersensitivity reactions may occur. Severe GI reactions may occur. Renal & hepatic impairment. Avoid skin & eye contact during reconstitution or administration. Avoid hepatotoxic drugs & alcohol during chemotherapy. Pregnancy & lactation.
Adverse Reactions
Anemia, leukopenia & thrombocytopenia; anorexia, nausea & vomiting.
Drug Interactions
Drugs metabolised by CYP450 (CYP1A1, CYP1A2 & CYP2E1) & oral anticoagulants. May enhance effects of methoxypsoralen. Risk of serious & potentially fatal infections w/ live vaccines. Reduced absorption of phenytoin. May cause excessive immunosuppression & lymphoproliferation w/ cyclosporine & tacrolimus. May cause acute pulmonary toxicity (adult resp distress syndrome) w/ fotemustine.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01AX04 - dacarbazine ; Belongs to the class of other alkylating agents. Used in the treatment of cancer.
DTI for Injection inj 100 mg
DTI for Injection inj 200 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in